Physician profile
Rabia Moukrad
NPI 1962048314
$6,051.34
in general payments reported to CMS, 2019-2025
29 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,077 · 2022: $2,718 · 2024: $50.90 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,678.73 | 2021-2022 | |
| Novo Nordisk INC | $780.79 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $715.28 | 2021-2022 | |
| Abbvie INC. | $629.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $452.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $265.88 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $215.21 | 2021-2022 | |
| Mannkind Corporation | $186.19 | 2021 | |
| Pfizer INC. | $151.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $94.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $93.01 | 2022 | |
| Collegium Pharmaceutical, INC. | $92.24 | 2021-2022 | |
| Amgen INC. | $85.83 | 2021-2022 | |
| Abiomed | $84.49 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.69 | 2021-2022 | |
| Amarin Pharma, INC. | $55.80 | 2021 | |
| Janssen Scientific Affairs, LLC | $50.90 | 2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $38.21 | 2021 | |
| Zealand Pharma US, INC. | $33.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.01 | 2021 | |
| Merck Sharp & Dohme LLC | $22.55 | 2021 | |
| Lundbeck LLC | $21.92 | 2021 | |
| Almatica Pharma LLC | $21.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2021 | |
| Lifescan, INC. | $17.19 | 2021 | |
| Genentech USA, INC. | $16.54 | 2021 | |
| Mayne Pharma Commercial LLC | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabia Moukrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.